Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $6.7550 (-11.47%) ($6.6450 - $6.7550) on Fri. Aug. 26, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 7.17% (three month average) | RSI | 46 | Latest Price | $6.7550(-11.47%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -0.6% a day on average for past five trading days. | Weekly Trend | TGTX declines -4.6% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XLK(97%) XLC(92%) SPY(91%) XLU(90%) XBI(89%) | Factors Impacting TGTX price | TGTX will decline at least -3.585% in a week (0% probabilities). UUP(-61%) TBT(-32%) USO(-25%) XOP(8%) TIP(11%) | | | | | Relative Volatility | | | | Market Trend Strength | -3.585% (StdDev 7.17%) | Hourly BBV | -2.3 () | Intraday Trend | 0% | | | |
|
Resistance Level | $7.12 | 5 Day Moving Average | $7.07(-4.46%) | 10 Day Moving Average | $7.3(-7.47%) | 20 Day Moving Average | $7.12(-5.13%) | To recent high | -19.8% | To recent low | 80.9% | Market Cap | $856m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |